<DOC>
	<DOCNO>NCT01292122</DOCNO>
	<brief_summary>The purpose study evaluate safety VCT-01 split-thickness skin graft ( STSG ) donor site wound assess select parameter heal VCT-01-treated donor site .</brief_summary>
	<brief_title>Safety Study VCT-01™ Split-Thickness Skin Graft Donor Site Wounds</brief_title>
	<detailed_description>An initial cohort 5 subject allocate Group A . When subject enrol Group A complete 14 day post-treatment follow-up , result donor site evaluation , histological analysis report adverse event review Investigator study Sponsor . If data suggestive clinical benefit follow treatment absent serious and/or unexpected adverse event , , opinion investigator , related treatment , remain subject enrol randomized Groups B , C D .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<criteria>1 . Subject least 18 year age 55 year age . 2 . Subject primary wound require treatment splitthickness skin graft ; graft harvest site skin graft previously obtain . If primary wind result thermal chemical burn , total body surface area must less 15 % . 3 . Females childbearing potential must document negative urine pregnancy test must agree use highly effective contraceptive 6 month posttreatment . 4 . Subject read , understood sign Health Research Ethics Boardapproved Informed Consent Form . 5 . Subject able willing comply study procedure instruction . 1 . Female subject pregnant lactating . 2 . Clinically significant disease condition may compromise graft take and/or donor site healing ( e.g . presence bleed disorder , capillary fragility , venous arterial disorder directly affect donor site treat , know suspected systemic malignancy , human immunodeficiency virus infection , renal liver disease , uncontrolled diabetes mellitus , thrombocytopenia , vasculitis , poor nutritional status ) . 3 . Subjects currently receive receive within two month prior treatment : systemic , inhaled intranasal corticosteroid immunosuppressant agent . Subjects receive therapeutic dos anticoagulant preexist medical condition ( e.g . Plavix , Coumadin , Heparin , low molecular weight Heparin , nonsteroidal antiinflammatory drug , herbal supplement ) , dose interruption Screening 2Months posttreatment ( pretreatment / treatment / biopsy phase ) contraindicate , exclude study . 4 . Any disorder ( psychiatric , alcohol substance abuse [ within 12 month treatment ] , physical disability ) might interfere obtain informed consent subject 's ability comply study protocol requirement , determine Investigator . 5 . Subjects use tobacco product within 3 month prior treatment . 6 . Subjects previously treat Apligraf® , Dermagraft cellbased product , include autologous tissue treatment site . 7 . Subjects receive investigational drug , device biological/bioactive treatment within 30 day prior treatment ( medical dental ) . 8 . Subjects , opinion Investigator , reason list , able complete study per protocol . 9 . Subjects , determine Screening immunology testing , specific antibody VCT01 donor cell human leukocyte antigen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Wounds</keyword>
	<keyword>Grafts</keyword>
	<keyword>Wound Healing</keyword>
	<keyword>Cell Therapy</keyword>
	<keyword>Split-thickness skin graft donor site wound</keyword>
</DOC>